Tourmaline_logo.jpg
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024 07:10 ET | Tourmaline Bio, Inc.
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024
Tourmaline_logo.jpg
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024 07:00 ET | Tourmaline Bio, Inc.
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline_logo.jpg
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024 07:00 ET | Tourmaline Bio, Inc.
Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024
Tourmaline_logo.jpg
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 19, 2024 07:00 ET | Tourmaline Bio, Inc.
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial...
Tourmaline_logo.jpg
Tourmaline Bio to Present at Upcoming Investor Conferences
February 27, 2024 07:30 ET | Tourmaline Bio, Inc.
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve...
Tourmaline_logo.jpg
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024 08:00 ET | Tourmaline Bio, Inc.
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve...
Tourmaline_logo.jpg
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 29, 2024 16:01 ET | Tourmaline Bio, Inc.
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline_logo.jpg
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
January 25, 2024 07:00 ET | Tourmaline Bio, Inc.
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline_logo.jpg
Tourmaline Bio Announces Proposed Public Offering of Common Stock
January 24, 2024 16:05 ET | Tourmaline Bio, Inc.
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline_logo.jpg
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
January 08, 2024 07:00 ET | Tourmaline Bio, Inc.
Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 ...